Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma-Reference-Cited by-同舟云学术

Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma

Published:2011-12-09 Issue:4 Volume:156 Page:490-498
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Barth Matthew J.,Hernandez-Ilizaliturri Francisco J.,Mavis Cory,Tsai Ping-Chiao,Gibbs John F.,Deeb George,Czuczman Myron S.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2011.08966.x/fullpdf

Reference35 articles.

1. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis;Beum;Journal of Immunology,2008

2. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene;Cartron;Blood,2002

3. Newer monoclonal antibodies for hematological malignancies;Castillo;Experimental Hematology,2008

4. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study;Coiffier;British Journal of Haematology,2010

5. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma;Cruz;Leukaemia & Lymphoma,2007

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baseline immunoglobulin G and immune function in non-Hodgkin lymphoma: a retrospective analysis;Frontiers in Immunology;2024-04-30

2. Maintenance therapy for chronic lymphocytic leukaemia;Cochrane Database of Systematic Reviews;2024-01-04

3. Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial;Bone Marrow Transplantation;2024-01-02

4. Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation;Biochimica et Biophysica Acta (BBA) - General Subjects;2023-11

5. Multi-targeted immunotherapeutics to treat B cell malignancies;Journal of Controlled Release;2023-06